A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 1, 2005, Pages 15-21

  Alexander, Richard L ^a   Greene, Bryan T ^a   Torti, Suzy V ^a   Kucera, Gregory L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Conjugates; Drug delivery; Gemcitabine; Phospholipid; Resistance

Indexed keywords

DEOXYCYTIDINE KINASE; DRUG ANALOG; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN 1; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GLYCOPROTEIN P; PHOSPHOLIPID; PRODRUG;

ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG PENETRATION; DRUG SENSITIVITY; DRUG TRANSPORT; HUMAN; HUMAN CELL; LIPOPHILICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; DRUG RESISTANCE; DRUG SCREENING; SOLUBILITY;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; P-GLYCOPROTEIN; PHOSPHOLIPIDS; PRODRUGS; SOLUBILITY; TUMOR CELLS, CULTURED;

EID: 21244454358     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0949-0     Document Type: Article

References (33)

1. Alexander RL, Morris-Natschke SL, Ishaq KS, Fleming RA, Kucera GL (2003) Synthesis and cytotoxic activity of two novel 1-dodecylthio-2-decyloxypropyl-3- phosphatidic acid conjugates with gemcitabine and cytosine arabinoside. J Med Chem 46:4205
2. Bergman AM, Pinedo HM, Peters GJ (2002) Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5:19
3. Bouffard DY, Laliberte J, Momparler RL (1993) Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 45:1857
4. Bouffard DY, Momparler RL (1995) Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res 19:849
5. Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, Cass CE (2003) Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22:7524
6. Galmarini CM, Mackey JR, Dumontet C (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15:875
7. Galmarini CM, Thomas X, Graham K, El Jafaari A, Cros E, Jordheim L, Mackey JR, Dumontet C (2003) Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol 122:53
8. Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, Dumontet C (2004) Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol 4:8
9. Hapke DM, Stegmann AP, Mitchell BS (1996) Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 56:2343
10. Hatzis P, Al Madhoon AS, Jullig M, Petrakis TG, Eriksson S, Talianidis I (1998) The intracellular localization of deoxycytidine kinase. J Biol Chem 273:30239
11. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38:567
12. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1992) Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 52:533
13. Heinemann V, Schulz L, Issels RD, Plunkett W (1995) Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 22:11
14. Herrmann DBJ, Opitz H-G, Kucera LS (1997) In vitro and in vivo evaluation of the new anti-AIDS compound Fozivudine. Naunyn Schmiedebergs Arch Pharmacol 356:R44
15. Huang P, Plunkett W (1995) Induction of apoptosis by gemcitabine. Semin Oncol 22:19
16. Kinsella AR, Smith D (1998) Tumor resistance to antimetabolites. Gen Pharmacol 30:623
17. Kroep JR, Loves WJ, Van der Wilt CL, Alvarez E, Talianidis L, Boven E, Braakhuis BJ, van Groeningen CJ, Pinedo HM, Peters GJ (2002) Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1:371
18. Kucera GL, Goff CL, Iyer N, Morris-Natschke S, Ishaq KS, Wyrick SD, Fleming RA, Kucera LS (2001) Cellular metabolism in lymphocytes of a novel thioether-phospholipid-AZT conjugate with anti-HIV-1 activity. Antiviral Res 50:129
19. Kucera LS, Iyer N, Morris-Natschke SL, Chen SY, Gumus F, Ishaq K, Herrmann DB (1998) In vitro evaluation and characterization of newly designed alkylamidophospholipid analogues as anti-human immunodeficiency virus type 1 agents. Antivir Chem Chemother 9:157
20. Lambert DM (2000) Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci 11:S15-S27
21. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58:4349
22. Martins LM, Kottke T, Mesner PW, Basi GS, Sinha S, Frigon N Jr, Tatar E, Tung JS, Bryant K, Takahashi A, Svingen PA, Madden BJ, McCormick DJ, Earnshaw WC, Kaufmann SH (1997) Activation of multiple interleukin-1beta converting enzyme homologues in cytosol and nuclei of HL-60 cells during etoposide-induced apoptosis. J Biol Chem 272:7421
23. Mizuno K, Furuhashi Y, Maeda O, Iwata M, Misawa T, Kawai M, Kano T, Tomoda Y (1990) Mitomycin C cross-resistance induced by adriamycin in human ovarian cancer cells in vitro. Cancer Chemother Pharmacol 26:333
24. Neff T, Blau CA (1996) Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 24:1340
25. Plunkett W (1994) Preclinical characteristics of cytarabine, gemcitabine, fludarabine and cladribine: relevance for clinical studies. In: Aapro MS (ed) Innovative antimetabolites n solid tumours. Springer-Verlag, New York, pp 11-19
26. Plunkett W, Huang P, Gandhi V (1995) Preclinical characteristics of gemcitabine. Anticancer Drugs 6 [Suppl 6]:7
27. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3
28. Polverino AJ, Patterson SD (1997) Selective activation of caspases during apoptotic induction in HL-60 cells. Effects of a tetrapeptide inhibitor. J Biol Chem 272:7013
29. Raetz CRH, Chu MY, Srivastava SP, Turcotte JG (1977) A phospholipid derivative of cytosine arabinoside and its conversion to phosphatidylinositol by animal tissue. Science 196:303
30. Reiman T, Graham KA, Wong J, Belch AR, Coupland R, Young J, Cass CE, Mackey JR (2002) Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study. Leukemia 16:1886
31. Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM, Peters GJ (1994) Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54:4138
32. Ryu EK, Ross RJ, Matsushita T, MacCoss M, Hong CI, West CR (1982) Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5′-monophosphate-L-1,2- dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2- diacylglycerols. J Med Chem 25:1322
33. Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki K, Tsuruo T, Cowan KH, Glazer RI (1991) Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 3:181